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Objectives: Anti-cancer chemotherapeutic pharmaceutical agents have some 
toxic effects to normal cells. Therefore, the main factors to increase therapeutic 
effects are to destroy cancer cells specifically and appropriate dosage of anti-
cancerous agents. Cancer cells are have being studied in many ways by using cell 
culture technologies in developed countries. We aimed to determine the chemo-
sensitivity of colorectal cancer cases. MethOds: From February 2013 through 
February 2014, Histoculture drug response assay data were obtained from 6 colo-
rectal cancer surgical specimens held in State Central Hospital. Cultures and 
culture media were prepared by R. Hoffmans methods. We examined chemosen-
sitivities of the tissue to carboplatin, irinotecan, doxorubicin, 5-fluorouracil and 
oxalaplatin. Cutoff inhibition rates were determined with each drug for colorectal 
cancer and were used to calculate predictabilities for chemosensitivity responses. 
We also prepared double samples from the culture and made histologic and cyto-
logic analysis. Results: The evaluability of the histoculture drug response assay 
was at 83,3%. Predictability including true-positive and true-negative rates of 83,3% 
and 100% was observed. cOnclusiOns: Cancer cells deaths are dependent from 
dosages of the candidate medications and it shows it is possible to use drug sen-
sitivity methods in oncologic clinical practice.
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Objectives: Various studies exploring the routine use of corticosteroids for man-
agement of acute respiratory distress syndrome have had controversial results. 
The aim of this study was to evaluate and compare randomized, controlled trials 
with observational studies (comparing historical controls) determining the effi-
cacy and safety of steroids in management of Acute Respiratory Distress Syndrome 
in adult population. MethOds: English language, randomized control trial and 
observational studies were searched using different  databases like the Cochrane 
Central Register of Controlled Trials, Cochrane database of systematic reviews, 
PUBMED, SCOPUS, SCIENCE DIRECT (Key terms: corticosteroids, methylprednisolone, 
hydrocortisone, dexamethasone AND acute lung injury, adult respiratory distress syn-
drome, acute respiratory distress syndrome, ARDS, respiratory failure, septic shock; years: 
inception to February 2014). Results: A total of 8 randomized control trial and 5 
observational studies using variable dose and duration of steroids met the inclu-
sion criteria. The Mantel-Hanzel odds ratio of corticosteroids decreasing mortality 
in patients of randomized, controlled trial was 0.822; 95% CI 0.480 to 1.408 whereas 
in observational studies was 0.552; 95% CI 0.134 to 2.278. The odds of corticoster-
oids associated infectious complications in patients of randomized, controlled 
trial was 1.118; 95% CI 0.557 to 2.247 whereas in observational studies was 1.662; 
95% CI 0.981 to 2.816. cOnclusiOns: A definitive role of corticosteroids in ARDS 
has not been established. However, current data from studies shows the result 
favouring use of corticosteroids in ARDS by decreasing the mortality associated. 
However, use of steroids is associated with a slight risk of increased infectious 
complications.
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Objectives: Acute respiratory distress syndrome (ARDS) is an acute hypoxemic 
respiratory failure. It is the most severe form of acute lung injury. The treatment 
of ARDS is generally supportive and there is ambiguity in the role of glucocorti-
coids in the treatment of ARDS. This study aimed at analyzing treatment pattern 
and outcome of patients in ARDS. MethOds: A retrospective observational study 
was conducted in a tertiary care teaching hospital. All the patients diagnosed 
with ARDS confirmed by chest X-ray and arterial blood gas during 2011 were 
included. Cases were identified and collected from the medical records division 
using ICD code J86. Results: A total of 150 patients diagnosed with ARDS were 
included in the study. Mean age of the study population was 43.37 ± 16.15 years. 
Majority of them were males, 60.7% of the population. Analyzing the treatment 
pattern, 98.6% were given antibiotics for their underlying conditions along with 
supportive therapies, 48.6% of patients received glucocorticoid therapy and was 
found to be beneficial. Outcome analysis revealed 50.7% of patients recovered 
and 45.3% expired. Higher mortality (56.4%) was observed in the group who did 
not receive glucocorticoid therapy compared to the group which received gluco-
corticoid therapy (41.7%). cOnclusiOns: The overall mortality rate was found 
to be high in ARDS patients in this study and use of glucocorticoids showed ben-
eficial effects.
Objectives: The aim of this study was to analyze the tuberculosis-related medical 
resource utilization pattern among new smear positive pulmonary tuberculosis 
(PTB) patients. We also estimated the cost of tuberculosis (TB) treatment from the 
perspective of provider and patient, and identified the significant cost driving fac-
tors. MethOds: All new smear positive PTB patients who were registered at the 
chest clinic of Penang General Hospital, between March 2010 and February 2011, 
were invited to participate in the study. Provider sector costs were estimated using 
bottom-up, micro-costing technique. For the calculation of costs from the patients’ 
perspective, all eligible patients who agreed to participate in the study were inter-
viewed after the intensive phase and at end of their treatment by a trained nurse. 
Predictive Analysis SoftWare was used to analyze the data. Results: During the 
study period, 226 patients completed the treatment. However, complete costing 
data were available for 212 patients. The most highly utilized resource was chest 
X-rays followed by sputum smear examination and non-specific laboratory tests. 
Only a smaller proportion of the patients were hospitalized. The total cost of treat-
ing a smear positive PTB patient was USD 727.24. The amount paid by the patient 
constituted 55.3% (USD 401.90) of the total average cost of TB treatment. In multiple 
linear regression analysis, prolonged treatment duration (i.e., > 6 months) was the 
only predictor of higher provider sector cost, whereby higher patient sector cost 
were determined by greater household income and persistent cough at the end of 
the intensive phase of the treatment. cOnclusiOns: The average provider sector 
cost was 1.45 times higher (USD 325.35 versus USD 225.00) than the budget allocated 
by the Ministry of Health for the treatment of a TB case in Malaysia. The expenses 
borne by the patients and their families accounted for 5.71% of their annual family 
income, hence not catastrophic.
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Objectives: Chronic diseases are common and costly to society, but often pre-
ventable. This study focuses on better understanding awareness and prevention of 
chronic diseases in Japan. MethOds: This study included data for the 2012 Japan 
(N= 30,000) National Health and Wellness Survey, a cross-sectional, Internet-based 
survey of adults (18+ years) who provide information on their comorbidities, and 
health care behaviors. Awareness of chronic diseases were assessed using the 
following question: “Which of the following conditions are you aware of (COPD, 
depression, diabetes, hypertension, dyslipidemia and osteoporosis)?”. Prevention 
was assessed with the following question: “Which conditions to do take steps to 
prevent (heart attack/heart problems/stroke/mini-stroke, diabetes, osteoporosis)?”. 
Risk groups of COPD, depression, diabetes, hypertension, dyslipidemia and osteo-
porosis were calculated. Results were weighted/projected to represent the total 
population based on the Census Bureau. Results: In Japan, 19.8%, 79.1%, 78.4%, 
77.6%, 63.2%, 71.0% report awareness of COPD, depression, diabetes, hypertension, 
dyslipidemia, and osteoporosis, respectively. Within the risk groups only 25.1%, 
82.7%, 87.0%, 82.4%, 81.9%, 81.1% report awareness of COPD, depression, diabetes, 
hypertension, dyslipidemia, and osteoporosis, respectively. Overall, 4.4% of respond-
ents were taking steps to prevent heart problems, 7.7% were taking steps to prevent 
diabetes and 5.7% were taking steps to prevent osteoporosis. Among the COPD risk 
group, 36.5% quit smoking and 41.8% of the depression risk group spoke to a health 
care provider in the past six months. Within the diabetes risk groups 46.8% were 
taking steps to prevent diabetes. Only 6.5% of hypertension and 7.7% of dyslipidemia 
risk respondents were taking steps to prevent heart problems. In the osteoporosis 
risk group only 15.5% where taking steps to prevent osteoporosis. cOnclusiOns: 
Data suggests a need for education programs to build awareness of chronic diseases 
in Japan. Due to the lack of knowledge of chronic diseases in Japan, prevention is 
limited especially amongst the at risk groups.
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Objectives: The purpose of this study was to examine cost-effectiveness of 
varenicline, a pharmacotherapy developed to support smoking cessation, versus 
currently available alternatives. MethOds: Two analytic decision tree models were 
used to simulate effectiveness of varenicline versus bupropion and varenicline ver-
sus nicotine replacement therapy (NRT). A 30-year Markov model with health states 
“Smoker”, “Quitter” and “Dead” was used for a hypothetical cohort of Korean smok-
ers who are over 30 years old and willing to quit smoking. The population entered in 
the model received three months of therapy. Utility values of smokers and quitters 
incorporated in the model were collected from local data. Transition probabilities 
were from clinical trials and local statistic data, and cost data were obtained from 
Korean health insurance reimbursement price list and local market price for non-
reimbursement products. The model used a 5% discount rate for costs and effective-
ness. Sensitivity analyses were conducted on various parameters such as the time 
to reach mortality rate of ex-smokers compared to that of non-smokers, time hori-
zon and discount rate. Results: The effectiveness of varenicline compared with 
bupropion and NRT was greater while it was more costly than both. The incremental 
effectiveness of varenicline versus bupropion and NRT was similar at 77,965 QALYs. 
The incremental cost of varenicline versus bupropion was 826 billion KRW and 
1,428 billion KRW with NRT. The ICER of varenicline comparing to bupropion and 
NRT were estimated at 10.6 million KRW per QALY and 19 million KRW per QALY, 
respectively. Sensitivity analyses were quite robust for all parameters but it was 
most sensitive to time horizon. cOnclusiOns: Varenicline treatment for smoking 
cessation can be considered as cost-effective compared with existing therapies in 
Korea. The ICER becomes lower when morbidity rates of smoking related diseases 
are reflected.
